Aurora's Safari Flower Secures EU-GMP Certification for Niagara Facility
Event summary
- Safari Flower Company, a subsidiary of Aurora Cannabis, received EU-GMP certification for its Ontario facility on July 23, 2026.
- The certification is valid for a three-year term and strengthens Safari's ability to serve international medical cannabis markets.
- Aurora acquired Safari Flower Company in April 2026 to expand its EU-GMP capacity and support global medical cannabis supply.
- Safari's facility is a 59,000 square foot cultivation and manufacturing site in the Niagara Region of Ontario.
The big picture
Aurora Cannabis is strengthening its position as a global leader in medical cannabis by leveraging Safari Flower Company's EU-GMP certified facility. This strategic move aligns with Aurora's goal of expanding its global footprint and delivering high-quality cannabis products to regulated markets. The certification underscores the importance of compliance and operational excellence in the evolving international medical cannabis landscape.
What we're watching
- Market Expansion
- How Safari's EU-GMP certification will impact Aurora's market share in key European countries like Germany, Poland, and the UK.
- Regulatory Compliance
- Whether Aurora can sustain its compliance standards across its global manufacturing network.
- Operational Efficiency
- The pace at which Safari can scale production to meet growing demand in international medical cannabis markets.
Related topics